Skip to content

Pulmonary Vein Antrum Isolation (PVAI) Plus Scar Homogenization and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation

PVAI Plus Scar Homogenization and Ablation of Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01672138
Acronym
TANTRA
Enrollment
186
Registered
2012-08-24
Start date
2013-02-28
Completion date
2020-12-31
Last updated
2018-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long-standing Persistent Atrial Fibrillation, Persistent Atrial Fibrillation

Keywords

PVAI, NPAF, Non-PV triggers

Brief summary

This study aims to examine the long-term success rate of catheter ablation in non-paroxysmal atrial fibrillation patients using different ablation strategies such as : (i) pulmonary vein antrum isolation (PVAI) + isolation of left atrial posterior wall, (ii) PVAI plus scar homogenization, (iii) PVAI plus isolation of posterior wall plus ablation of non-PV triggers \[ PVAI: Pulmonary Vein Antrum Isolation Non-PV triggers: Triggers arising from sites other than pulmonary veins\]

Detailed description

Back ground: Pulmonary vein antrum isolation (PVAI) as a lone procedure, is known to have limited success rate in terms of long-term recurrence-free survival in non-paroxysmal atrial fibrillation (NPAF) and additional ablations isolating extra-PV triggers seem to improve the outcome (1). The extra-PV triggers include triggers from other sites such as left atrial posterior wall, superior vena cava, interatrial septum, crista terminalis, left atrial appendage and coronary sinus (1, 2). These are known to be independent predictors of late AF recurrence following catheter ablation (3, 4, and 5). Earlier studies have demonstrated better ablation outcome in NPAF when non-PV triggers sites were isolated along with PVAI (5, 6). Moreover, Verma et al had reported high (57%) recurrence rate post-index procedure in AF patients with pre-existent scar (7). However, published data are conflicting regarding the benefits of additional substrate guided ablation (scar homogenization) compared to conventional PVAI alone strategy (8). Also, limited data is available showing a comparison of the lasting efficacy of the above three procedures when used in different combinations. Hypothesis: The combined ablation strategy including PVAI, scar homogenization and ablation of extra-PV triggers has the highest likelihood of maintaining long-term sinus rhythm in patients with NPAF.

Interventions

PROCEDURENon-PV triggers ablation

PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites

PROCEDUREPulmonary Vein Antrum Isolation

Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall

PROCEDUREscar homogenization

PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.

Sponsors

RCCS Monzino Hospital, Milan, Italy
CollaboratorUNKNOWN
Ospedale dell'Angelo, Venezia-Mestre
CollaboratorOTHER
Texas Cardiac Arrhythmia Research Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years 2. Patients undergoing first catheter ablation for drug-refractory Persistent (PerAF) or long-standing persistent AF (LSPAF) 3. Ability to understand and provide signed informed consent

Exclusion criteria

1. Previous catheter ablation or MAZE procedure in left atrium 2. Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of atrial arrhythmia3 yearsAny episode of AF/AT (atrial tachycardia) longer than 30 seconds will be considered as recurrence). Episodes that occur during the first 3 months of the procedure (blanking period) will not be considered as recurrence.

Secondary

MeasureTime frameDescription
Improvement in quality of life3 yearsImprovement in quality of life

Countries

United States

Contacts

Primary ContactAndrea Natale, MD
dr.natale@gmail.com
Backup ContactMitra Mohanty, MD
mitra.mohanty@stdavids.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026